Barinthus Biotherapeutics
BRNS
BRNS was delisted on the 8th of September, 2026.
11 hedge funds and large institutions have $31.2M invested in Barinthus Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
13% more capital invested
Capital invested by funds: $27.5M → $31.2M (+$3.71M)
10.2% more ownership
Funds ownership: 16.93% → 27.13% (+10%)
15% less funds holding
Funds holding: 13 → 11 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGIM
M&G Investment Management
London,
United Kingdom
|
+$17.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.19M |
| 2 |
Millennium Management
New York
|
-$132K |
| 3 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$70.1K |
| 4 |
Morgan Stanley
New York
|
-$5.27K |
BRNS Hedge Fund Activity: Q3 2022 in Review
11 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2022, worth a combined $31.2M — up 13% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BRNS and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was M&G Investment Management, adding an estimated $17.4M. The largest seller was Tudor Investment Corp, exiting entirely with an estimated $1.19M sold.
- 11 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $31.2M of Barinthus Biotherapeutics stock for Q3 2022, up 13% quarter-over-quarter.
- 0 funds opened new Barinthus Biotherapeutics positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest Barinthus Biotherapeutics buyer in Q3 2022 was M&G Investment Management, an estimated $17.4M added.
- The largest Barinthus Biotherapeutics seller in Q3 2022 was Tudor Investment Corp, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2022.